RedHill Biopharma (RDHL) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. QGEN
7. CSX
8. LRCX
9. NDAQ
10. BFH

Go back to RedHill Biopharma (RDHL) Misses Q2 EPS by 4c

RedHill Biopharma Announces Q3/22 Results and Operational Highlights

November 29, 2022 8:00 AM EST

Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth

Q3/22 Net revenues of $17.6 million; Operating loss of $7.1 million; Q3/22 positive cash flow from U.S. commercial operations, before interest payments[1]; Cash balance[2] of $31.4 million as of September 30, 2022

Talicia® and Movantik® have delivered year-to-date prescription growth of 65% and 6.7%, respectively; Q4/22 data to date indicate continued growth for both products

Discussions underway regarding opaganib for nuclear radiation injury with various government agencies with expedited Animal Rule pathway expected, and potential eligibility for a... More